Verdad Advisers’s AnaptysBio ANAB Stock Holding History

Verdad Advisers’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$236K	Buy	+3,498	New	+$212K	0.23%	136

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Verdad Advisers's ANAB Position: Q2 2026 in Review

Verdad Advisers opened a new position in AnaptysBio (ANAB) in Q2 2026: 3,498 shares worth $236K. The stake represents 0.23% of the portfolio and ranks #136 among its holdings.

213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Verdad Advisers held 3,498 shares of AnaptysBio worth $236K as of Q2 2026.
AnaptysBio was a new Verdad Advisers position in Q2 2026.
AnaptysBio made up 0.23% of Verdad Advisers's portfolio in Q2 2026, its #136 holding.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.